Related Experiment Video
Updated: Apr 19, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.1K
[Targeted radionuclide therapy for castration-resistant prostate cancer]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 19, 2014
Summary
Targeted radionuclide therapy offers hope for castration-resistant prostate cancer patients with bone metastases. Strontium-89 and radium-223 show promise in managing pain and improving survival, enhancing quality of life.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Castration-resistant prostate cancer (CRPC) commonly presents with bone metastases.
- Patients with bone metastases in CRPC often have a relatively favorable prognosis.
- Maintaining or improving patient quality of life is crucial.
Purpose of the Study:
- To review the role of targeted radionuclide therapy in CRPC.
- To focus on the applications of strontium-89 and radium-223 for bone metastases.
- To highlight advancements in managing CRPC bone metastases.
Main Methods:
- Review of existing literature on targeted radionuclide therapy.
- Focus on strontium-89 and radium-223 agents.
- Analysis of clinical trial data and therapeutic outcomes.
Main Results:
- Strontium-89 is approved in Japan for managing bone metastasis pain.
- Radium-223 demonstrates a survival advantage in CRPC patients with bone metastases.
- Both agents represent significant advancements in CRPC treatment.
Conclusions:
- Targeted radionuclide therapy is a valuable approach for CRPC with bone metastases.
- Strontium-89 and radium-223 are key agents in this therapeutic area.
- Further research and application of these therapies can improve patient outcomes and quality of life.
